Erratum (DOI:10.1016/j.biopsych.2007.05.001);Mood and Neuroendocrine Response to a Chemical Stressor, Metyrapone, in Buprenorphine-Maintained Heroin Dependence

Biological Psychiatry

Volumn 63, Issue 2, 2008, Pages 172-177

  Kakko, Johan ^a   von Wachenfeldt, Joachim ^a   Svanborg, Kerstin Dybrandt ^a   Lidström, Jessica ^b   Barr, Christina S ^b   Heilig, Markus ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

ACTH; cortisol; heroin; mood; stress

Indexed keywords

ADENINE; BUPRENORPHINE; CORTICOTROPIN; DIAMORPHINE; GUANINE; HYDROCORTISONE; METYRAPONE; NALTREXONE;

ADULT; AFFECT; ARTICLE; BEHAVIORAL STRESS; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEROIN DEPENDENCE; HETEROZYGOSITY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAINTENANCE THERAPY; MALE; MOOD CHANGE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROFILE OF MOOD STATES; PSYCHOLOGICAL RATING SCALE; RECEPTOR GENE; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 37349102679     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.07.021     Document Type: Erratum

References (40)

1. Kreek M.J., and Koob G.F. Drug dependence: Stress and dysregulation of brain reward pathways. Drug Alcohol Depend 51 (1998) 23-47
2. Kreek M.J., LaForge K.S., and Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov 1 (2002) 710-726
3. Houshyar H., Gomez F., Manalo S., Bhargava A., and Dallman M.F. Intermittent morphine administration induces dependence and is a chronic stressor in rats. Neuropsychopharmacology 28 (2003) 1960-1972
4. Gerra G., Baldaro B., Zaimovic A., Moi G., Bussandri M., Raggi M.A., et al. Neuroendocrine responses to experimentally-induced emotions among abstinent opioid-dependent subjects. Drug Alcohol Depend 71 (2003) 25-35
5. Sapolsky R.M. Stress and plasticity in the limbic system. Neurochem Res 28 (2003) 1735-1742
6. Gould E., and Gross C.G. Neurogenesis in adult mammals: Some progress and problems. J Neurosci 22 (2002) 619-623
7. Lee A.L., Ogle W.O., and Sapolsky R.M. Stress and depression: Possible links to neuron death in the hippocampus. Bipolar Disord 4 (2002) 117-128
8. Kreek M.J., and Koob G.F. Drug dependence: Stress and dysregulation of brain reward pathways. Drug Alcohol Depend 51 (1998) 23-47
9. Koob G.F., and Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci 8 (2005) 1442-1444
10. Shaham Y., Funk D., Erb S., Brown T.J., Walker C.D., and Stewart J. Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. J Neurosci 17 (1997) 2605-2614
11. Schulkin J., Gold P.W., and McEwen B.S. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: Implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology 23 (1998) 219-243
12. Makino S., Hashimoto K., and Gold P.W. Multiple feedback mechanisms activating corticotropin-releasing hormone system in the brain during stress. Pharmacol Biochem Behav 73 (2002) 147-158
13. Vyas A., Bernal S., and Chattarji S. Effects of chronic stress on dendritic arborization in the central and extended amygdala. Brain Res 965 (2003) 290-294
14. Roozendaal B. Glucocorticoids and the regulation of memory consolidation (1999 Curt P. Richter award). Psychoneuroendocrinology 25 (2000) 213-238
15. Kreek M.J., Wardlaw S.L., Hartman N., Raghunath J., Friedman J., Schneider B., et al. Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci 33 suppl 1 (1983) 409-411
16. Mattick R.P., Kimber J., Breen C., and Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. [update of Cochrane Database Syst Rev 2003;(2):CD002207; PMID: 12804429]. Cochrane Database Syst Rev 3 (2004) CD002207
17. Kakko J., Svanborg K.D., Kreek M.J., and Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet 361 (2003) 662-668
18. Kirchmayer U., Davoli M., and Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2 (2000) CD001333
19. Kosten T.R., Kreek M.J., Ragunath J., and Kleber H.D. Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biol Psychiatry 21 (1986) 217-220
20. Schluger J.H., Borg L., Ho A., and Kreek M.J. Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacology 24 (2001) 568-575
21. Bond C., LaForge K.S., Tian M.T., Melia D., Zhang S.W., Borg L., et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci U S A 95 (1998) 9608-9613
22. Bart G., Heilig M., LaForge K.S., Pollak L., Leal S.M., Ott J., et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry 9 (2004) 547-549
23. Wand G.S., McCaul M., Yang X., Reynolds J., Gotjen D., Lee S., et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26 (2002) 106-114
24. McNair D.M., Lorr M., and Droppleman L.F. Profile of Mood States (Manual) (1971), Educational and Industrial Testing Service, San Diego
25. Lindgren K.N., Masten V.L., Tiburzi M.J., Ford D.P., and Bleecker M.L. The factor structure of the profile of mood states (POMS) and its relationship to occupational lead exposure. J Occup Environ Med 41 (1999) 3-10
26. Kreek M.J., Ragunath J., Plevy S., Hamer D., Schneider B., and Hartman N. ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 5 (1984) 277-278
27. Vescovi P.P., Gerra G., Maninetti L., Pedrazzoni M., Michelini M., Pioli G., et al. Metyrapone effects on beta-endorphin, ACTH and cortisol levels after chronic opiate receptor stimulation in man. Neuropeptides 15 (1990) 129-132
28. Mutti A., Folli D., Van der Venne M.T., Berlin A., Gerra G., Caccavari R., et al. Long-lasting impairment of neuroendocrine response to psychological stress in heroin addicts. Neurotoxicology 13 (1992) 255-260
29. Gerra G., Zaimovic A., Raggi M.A., Giusti F., Delsignore R., Bertacca S., et al. Aggressive responding of male heroin addicts under methadone treatment: Psychometric and neuroendocrine correlates. Drug Alcohol Depend 65 (2001) 85-95
30. Mangold D.L., and Wand G.S. Cortisol and adrenocorticotropic hormone responses to naloxone in subjects with high and low neuroticism. Biol Psychiatry 60 (2006) 850-855
31. Spanagel R., Herz A., and Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A 89 (1992) 2046-2050
32. Johnson S.W., and North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12 (1992) 483-488
33. Vaccarino F.J., Amalric M., Swerdlow N.R., and Koob G.F. Blockade of amphetamine but not opiate-induced locomotion following antagonism of dopamine function in the rat. Pharmacol Biochem Behav 24 (1986) 61-65
34. Amalric M., and Koob G.F. Low-doses of methylnaloxonium in the nucleus accumbens antagonize hyperactivity induced by heroin in the rat. Pharmacol Biochem Behav 23 (1985) 411-415
35. Bradley B.P., Phillips G., Green L., and Gossop M. Circumstances surrounding the initial lapse to opiate use following detoxification. Br J Psychiatry 154 (1989) 354-359
36. Childress A.R., Ehrman R., McLellan A.T., MacRae J., Natale M., and O'Brien C.P. Can induced moods trigger drug-related responses in opiate abuse patients?. J Subst Abuse Treat 11 (1994) 17-23
37. Janiri L., Martinotti G., Dario T., Reina D., Paparello F., Pozzi G., et al. Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: A correlation study. Neuropsychobiology 52 (2005) 37-44
38. Dawe S., and Gray J.A. Craving and drug reward: A comparison of methadone and clonidine in detoxifying opiate addicts. Drug Alcohol Depend 39 (1995) 207-212
39. Heinz A., Lober S., Georgi A., Wrase J., Hermann D., Rey E.R., et al. Reward craving and withdrawal relief craving: Assessment of different motivational pathways to alcohol intake. Alcohol Alcohol 38 (2003) 35-39
40. Gerra G., Zaimovic A., Zambelli U., Delsignore R., Baroni M.C., Laviola G., et al. Neuroendocrine correlates of depression in abstinent heroin-dependent subjects. Psychiatry Res 96 (2000) 221-234